Amphetamine-Related Disorders Clinical Trial
Official title:
Implementation and Effectiveness of Multidiscipline-Integrated Addiction Treatment Model
Management of substance use disorders in clinical settings is challenging. Approaches with
integrated bio-psycho-social interventions, along with the engagement of families and
self-help groups are strongly recommended. The Matrix intensive outpatient program has been
developed in UCLA to help the psychostimulant misusers in the Southern California in 1980's.
With integration of the existing evidence of addiction researches and empirically supported
cognitive-behavior treatment techniques, the Matrix model developed manuals to address
knowledge and skills needed for drug users in their early recovery and relapse prevention.
The treatment was delivered in a 16-week intensive structured group sessions. There was also
a 12-week educational sessions for the in-treatment individuals and their families. A
substantial body of evidence has demonstrated the successful experience of the Matrix
treatment model in management a broad spectrum of addictive disorders in many countries.
The objectives of the pilot project are to set up a multi-center collaborative clinical
network with implementation of an integrated addiction treatment program modified from the
UCLA Matrix model. Via the establishment of standardized subject recruitment criteria,
treatment and outcome assessment procedures, the study aims to assess the adherence of
participating clinical organizations to the study protocol, the acceptance of participating
MA misusers for the integrated treatment program as well as the outcomes and their
determinants for the treatment models.
Methamphetamine (MA) use disorder is a serious legal and health problem worldwide. Reports
from Ministry of Justice in Taiwan revealed that the MA-related crimes has tremendously
increased over the past decade. The arrested users of scheduled II drugs, MA mainly, has
surged from 34,886 in 2014 to 54,190 in 2016 in Taiwan. It is critical to tackle the emerging
problems in Taiwan.
Management of MA use disorder in clinical settings is challenging. Approaches with integrated
bio-psycho-social interventions, along with the engagement of families and self-help groups
are strongly recommended. The Matrix intensive outpatient program has been developed in UCLA
to help the psychostimulant misusers in the Southern California in 1980's.With integration of
the existing evidence of addiction researches and empirically supported cognitive-behavior
treatment techniques, the Matrix model developed manuals to address knowledge and skills
needed for drug users in their early recovery and relapse prevention. The treatment was
delivered in a 16-week intensive structured group sessions. There was also a 12-week
educational sessions for the in-treatment individuals and their families. A substantial body
of evidence has demonstrated the successful experience of the Matrix treatment model in
management a broad spectrum of addictive disorders in many countries.
The objectives of the pilot project are to set up a multi-center collaborative clinical
network with implementation of an integrated addiction treatment program modified from the
UCLA Matrix model. Via the establishment of standardized subject recruitment criteria,
treatment and outcome assessment procedures, the study aims to assess the adherence of
participating clinical organizations to the study protocol, the acceptance of participating
MA misusers for the integrated treatment program as well as the outcomes and their
determinants for the treatment models.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02232789 -
Abuse Liability and Human Pharmacology of Mephedrone
|
Phase 1 | |
| Completed |
NCT01449565 -
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
|
Phase 2 | |
| Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
| Active, not recruiting |
NCT00100074 -
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00033072 -
Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
|
Phase 1 | |
| Recruiting |
NCT06145698 -
Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD
|
N/A | |
| Completed |
NCT00990067 -
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
|
Phase 1 | |
| Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
| Recruiting |
NCT01899313 -
A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence
|
N/A | |
| Active, not recruiting |
NCT00265278 -
Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00000350 -
Effects of Stimulant Dependence on Human Striatal Dopamine System - 15
|
Phase 1 | |
| Active, not recruiting |
NCT00089440 -
Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
|
Phase 1 | |
| Active, not recruiting |
NCT00040040 -
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
|
Phase 1 | |
| Completed |
NCT00040053 -
Ondansetron for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 | |
| Completed |
NCT00895804 -
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
|
Phase 1 | |
| Recruiting |
NCT03902405 -
Computerized Exercise to Alter Stimulant Approach Responses
|
N/A | |
| Recruiting |
NCT04982796 -
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
|
Phase 1/Phase 2 | |
| Completed |
NCT01386177 -
Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT01136278 -
Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)
|
Phase 1 | |
| Completed |
NCT00069251 -
Bupropion for the Treatment of Methamphetamine Dependence - 1
|
Phase 2 |